Brokerages Set Roche Holdings AG Basel ADR (RHHBY) Price Target at $34.50

Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) has earned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $34.50.

RHHBY has been the subject of several research reports. Cowen reaffirmed a “buy” rating and set a $34.00 price target on shares of Roche Holdings AG Basel in a research note on Thursday, July 26th. ValuEngine raised shares of Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a research note on Monday, July 30th. Bank of America cut shares of Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research note on Monday, September 10th. Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a research note on Wednesday, September 12th. Finally, Wolfe Research initiated coverage on shares of Roche Holdings AG Basel in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company.

Several large investors have recently added to or reduced their stakes in the stock. Chickasaw Capital Management LLC grew its stake in shares of Roche Holdings AG Basel by 5.0% in the second quarter. Chickasaw Capital Management LLC now owns 42,000 shares of the company’s stock valued at $1,166,000 after buying an additional 2,000 shares in the last quarter. Moloney Securities Asset Management LLC grew its stake in shares of Roche Holdings AG Basel by 7.8% in the third quarter. Moloney Securities Asset Management LLC now owns 34,977 shares of the company’s stock valued at $1,064,000 after buying an additional 2,525 shares in the last quarter. Todd Asset Management LLC grew its stake in shares of Roche Holdings AG Basel by 2.3% in the second quarter. Todd Asset Management LLC now owns 118,900 shares of the company’s stock valued at $3,285,000 after buying an additional 2,700 shares in the last quarter. Lenox Wealth Management Inc. grew its stake in shares of Roche Holdings AG Basel by 3.4% in the third quarter. Lenox Wealth Management Inc. now owns 118,812 shares of the company’s stock valued at $3,583,000 after buying an additional 3,886 shares in the last quarter. Finally, Pillar Pacific Capital Management LLC grew its stake in shares of Roche Holdings AG Basel by 3.0% in the third quarter. Pillar Pacific Capital Management LLC now owns 158,733 shares of the company’s stock valued at $4,830,000 after buying an additional 4,615 shares in the last quarter. 0.31% of the stock is owned by institutional investors and hedge funds.

RHHBY stock traded up $0.10 during mid-day trading on Monday, hitting $31.00. 1,022,160 shares of the company were exchanged, compared to its average volume of 1,467,975. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $207.70 billion, a P/E ratio of 15.90, a price-to-earnings-growth ratio of 1.84 and a beta of 0.53. Roche Holdings AG Basel has a 1-year low of $26.30 and a 1-year high of $32.42.

About Roche Holdings AG Basel

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Featured Story: Investing strategies using the yield curve

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply